# Tolebrutinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tolebrutinib

> Tolebrutinib, sponsored by Sanofi (SNY), received a complete response letter from the FDA; the decision is dated December 23, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | tolebrutinib |
| Codes | SAR442168 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Relapsing Multiple Sclerosis](https://sec-api.dev/indications/relapsing-multiple-sclerosis), Primary Progressive Multiple Sclerosis |
| Modality | small_molecule |
| FDA designations | breakthrough, priority review |

## Timeline

### September 28, 2025: PDUFA date

- Status: delayed. Date confidence: exact.
- First seen 2025-03-26, last confirmed 2025-04-24.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-077305): "Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025;" https://www.sec.gov/Archives/edgar/data/1121404/000119312525077305/d942506dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001121404-25-000013): "The target action date for the FDA decision is September 28, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-077305): "Drug Administration with a target action date of September 28, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312525077305/d942506dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-063669): "The target action date for the FDA decision is September 28, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312525063669/d939010dex991.htm

### November 14, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Primary Progressive Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04458051 (Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT04458051

### December 23, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219624_20251223.pdf%22

### December 28, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-09-22, last confirmed 2026-01-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-332163): "On December 15, 2025, Sanofi provided an update on the ongoing review which stated that: (i) FDA was expecting the review to go beyond the previously communicated revised US target action date of December 28, 2025; (ii) further guidance from the FDA was expected by the end of the first quarter of 2026; and (iii) in response to an FDA request, Sanofi had submitted an expanded access protocol for tolebrutinib in nrSPMS." https://www.sec.gov/Archives/edgar/data/1121404/000119312525332163/d65502dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001121404-26-000001): "Earlier in December, based on the latest discussions with the FDA, Sanofi had provided an update on the review, including the decision to go beyond the revised target action date of December 28, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-250744): "The revised target action date for the FDA decision is December 28, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001121404-25-000026): "The revised target action date for the FDA decision is December 28, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-211134): "The revised target action date for the FDA decision is December 28, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312525211134/d36300dex992.htm
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219624_20251223.pdf%22

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06372145 (A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06372145

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06372145 (A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06372145

## Same indication

- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Kesimpta (ofatumumab)](https://sec-api.dev/pdufa/ofatumumab) (NVS)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Remibrutinib oral treatment](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) (NVS)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)

Calendar months: [September 2025](https://sec-api.dev/fda-calendar/2025-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tolebrutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tolebrutinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tolebrutinib

```bibtex
@misc{secapidev_pdufa_tolebrutinib_20261116,
  title        = {Tolebrutinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tolebrutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tolebrutinib_20261116","title":"Tolebrutinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tolebrutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
